Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer

INTRODUCTION: Alectinib demonstrated clinical efficacy and an acceptable safety profile in two phase II studies (NP28761 and NP28673). Here we report the pooled efficacy and safety data after 15 and 18 months more follow-up than in the respective primary analyses. METHODS: Enrolled patients had ALK...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, James Chih-Hsin, Ou, Sai-Hong Ignatius, Petris, Luigi De, Gadgeel, Shirish, Gandhi, Leena, Kim, Dong-Wan, Barlesi, Fabrice, Govindan, Ramaswamy, Dingemans, Anne-Marie C., Crino, Lucio, Lena, Herve, Popat, Sanjay, Ahn, Jin Seok, Dansin, Eric, Golding, Sophie, Bordogna, Walter, Balas, Bogdana, Morcos, Peter N., Zeaiter, Ali, Shaw, Alice T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886236/
https://www.ncbi.nlm.nih.gov/pubmed/28689043
http://dx.doi.org/10.1016/j.jtho.2017.06.070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886236/
https://www.ncbi.nlm.nih.gov/pubmed/28689043
http://dx.doi.org/10.1016/j.jtho.2017.06.070

Ejemplares similares